Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK in r/r AML
NCT05734898Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR-NK in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
NKG2D CAR-NK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05734898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734898.